Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.40
CBST's Cash to Debt is ranked higher than
51% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. CBST: 0.40 )
CBST' s 10-Year Cash to Debt Range
Min: 0.19   Max: 35.27
Current: 0.4

0.19
35.27
Equity to Asset 0.48
CBST's Equity to Asset is ranked higher than
62% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CBST: 0.48 )
CBST' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.95
Current: 0.48

-0.48
0.95
Interest Coverage 0.70
CBST's Interest Coverage is ranked lower than
55% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBST: 0.70 )
CBST' s 10-Year Interest Coverage Range
Min: 0.31   Max: 7.41
Current: 0.7

0.31
7.41
F-Score: 5
Z-Score: 3.61
M-Score: -2.50
WACC vs ROIC
2.02%
4.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 10.54
CBST's Operating margin (%) is ranked higher than
89% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. CBST: 10.54 )
CBST' s 10-Year Operating margin (%) Range
Min: -2763   Max: 29.79
Current: 10.54

-2763
29.79
Net-margin (%) 5.59
CBST's Net-margin (%) is ranked higher than
87% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. CBST: 5.59 )
CBST' s 10-Year Net-margin (%) Range
Min: -3094.81   Max: 29.49
Current: 5.59

-3094.81
29.49
ROE (%) 4.49
CBST's ROE (%) is ranked higher than
88% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. CBST: 4.49 )
CBST' s 10-Year ROE (%) Range
Min: -5818.4   Max: 69.13
Current: 4.49

-5818.4
69.13
ROA (%) 2.10
CBST's ROA (%) is ranked higher than
88% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. CBST: 2.10 )
CBST' s 10-Year ROA (%) Range
Min: -73.44   Max: 20.9
Current: 2.1

-73.44
20.9
ROC (Joel Greenblatt) (%) 13.93
CBST's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. CBST: 13.93 )
CBST' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -300.09   Max: 141.6
Current: 13.93

-300.09
141.6
Revenue Growth (3Y)(%) 15.00
CBST's Revenue Growth (3Y)(%) is ranked higher than
85% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CBST: 15.00 )
CBST' s 10-Year Revenue Growth (3Y)(%) Range
Min: -41.3   Max: 209.9
Current: 15

-41.3
209.9
EBITDA Growth (3Y)(%) -43.60
CBST's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CBST: -43.60 )
CBST' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -46.9   Max: 93.6
Current: -43.6

-46.9
93.6
» CBST's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CBST Guru Trades in Q2 2014

Ken Fisher 36,450 sh (New)
Vanguard Health Care Fund 1,467,542 sh (+10.91%)
Murray Stahl 24,000 sh (unchged)
Steven Cohen 394,200 sh (unchged)
George Soros Sold Out
Lee Ainslie Sold Out
Pioneer Investments 358,881 sh (-2.62%)
Chuck Royce 211,600 sh (-3.77%)
RS Investment Management 390,565 sh (-22.64%)
Jim Simons 47,420 sh (-74.92%)
» More
Q3 2014

CBST Guru Trades in Q3 2014

Vanguard Health Care Fund 1,977,342 sh (+34.74%)
Pioneer Investments 338,388 sh (unchged)
Murray Stahl 24,000 sh (unchged)
RS Investment Management Sold Out
Jim Simons Sold Out
Ken Fisher 34,775 sh (-4.60%)
Chuck Royce 197,980 sh (-6.44%)
Steven Cohen 340,200 sh (-13.70%)
» More
Q4 2014

CBST Guru Trades in Q4 2014

Paul Singer 539,000 sh (New)
Eric Mindich 1,904,073 sh (New)
George Soros 120,000 sh (New)
First Eagle Investment 20,000 sh (New)
Mario Gabelli 236,700 sh (New)
Prem Watsa 20,200 sh (New)
Vanguard Health Care Fund 1,977,342 sh (unchged)
First Eagle Investment 200 sh (unchged)
Steven Cohen Sold Out
Chuck Royce Sold Out
Pioneer Investments Sold Out
Murray Stahl 19,000 sh (-20.83%)
Ken Fisher 2,150 sh (-93.82%)
» More
Q1 2015

CBST Guru Trades in Q1 2015

Ken Fisher Sold Out
Eric Mindich Sold Out
Vanguard Health Care Fund Sold Out
George Soros Sold Out
First Eagle Investment Sold Out
Prem Watsa Sold Out
Murray Stahl Sold Out
Paul Singer Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Cubist Pharmaceuticals Inc

Mario Gabelli's Top 5 Stock Picks
Mario Gabelli (Trades, Portfolio) is the founder of GAMCO Investors, a firm with $49.9 billion in assets under management across a range of funds. Investing at GAMCO centers on a fundamental, bottom-up approach. Read more...
Prem Watsa's Stock Buys and Sells of Q4
“Canadian Warren Buffett (Trades, Portfolio)” Prem Watsa (Trades, Portfolio) bought sparingly in the fourth quarter, as he saw “a disconnect between the financial markets and the underlying economic fundamentals,” he said in his third-quarter conference call. Read more...
Gabelli's Q4 Picks Include Acquisition Targets
Mario Gabelli (Trades, Portfolio) founded GAMCO Investors in 1977, which runs a variety of mutual and closed-end funds. The Gabelli Asset Fund manages $3.6 billion in assets as of the fourth quarter and is rated 4 stars by Morningstar. Read more...
Mario Gabelli's Top 5 New Stock Buys of Q4
GAMCO Investors, Mario Gabelli (Trades, Portfolio)’s, purchased 32 stocks in the fourth quarter, for 3% turnover in its portfolio of 861 stocks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 126.00
CBST's P/E(ttm) is ranked higher than
87% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 126.00 )
CBST' s 10-Year P/E(ttm) Range
Min: 7.41   Max: 3802.11
Current: 126

7.41
3802.11
Forward P/E 24.94
CBST's Forward P/E is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 24.94 )
N/A
PE(NRI) 135.90
CBST's PE(NRI) is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 135.90 )
CBST' s 10-Year PE(NRI) Range
Min: 7.56   Max: 244.68
Current: 135.9

7.56
244.68
P/B 5.01
CBST's P/B is ranked higher than
67% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. CBST: 5.01 )
CBST' s 10-Year P/B Range
Min: 1.85   Max: 81.28
Current: 5.01

1.85
81.28
P/S 7.23
CBST's P/S is ranked higher than
79% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. CBST: 7.23 )
CBST' s 10-Year P/S Range
Min: 1.98   Max: 36.83
Current: 7.23

1.98
36.83
PFCF 68.42
CBST's PFCF is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 68.42 )
CBST' s 10-Year PFCF Range
Min: 8.06   Max: 277.85
Current: 68.42

8.06
277.85
POCF 55.70
CBST's POCF is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 55.70 )
CBST' s 10-Year POCF Range
Min: 7.09   Max: 2357
Current: 55.7

7.09
2357
EV-to-EBIT 70.99
CBST's EV-to-EBIT is ranked higher than
90% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 70.99 )
CBST' s 10-Year EV-to-EBIT Range
Min: -341   Max: 265.1
Current: 70.99

-341
265.1
Shiller P/E 79.98
CBST's Shiller P/E is ranked higher than
93% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 79.98 )
CBST' s 10-Year Shiller P/E Range
Min: 22.92   Max: 105.2
Current: 79.98

22.92
105.2
Current Ratio 3.54
CBST's Current Ratio is ranked higher than
70% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CBST: 3.54 )
CBST' s 10-Year Current Ratio Range
Min: 0.9   Max: 14.48
Current: 3.54

0.9
14.48
Quick Ratio 3.29
CBST's Quick Ratio is ranked higher than
69% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CBST: 3.29 )
CBST' s 10-Year Quick Ratio Range
Min: 0.81   Max: 14.48
Current: 3.29

0.81
14.48
Days Inventory 64.74
CBST's Days Inventory is ranked higher than
93% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBST: 64.74 )
CBST' s 10-Year Days Inventory Range
Min: 60.95   Max: 848.31
Current: 64.74

60.95
848.31
Days Sales Outstanding 36.08
CBST's Days Sales Outstanding is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. CBST: 36.08 )
CBST' s 10-Year Days Sales Outstanding Range
Min: 13.52   Max: 128.67
Current: 36.08

13.52
128.67

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 1.40
CBST's Earnings Yield (Greenblatt) is ranked higher than
87% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CBST: 1.40 )
CBST' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 23.3
Current: 1.4

0.4
23.3
Forward Rate of Return (Yacktman) -14.01
CBST's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 14.83 vs. CBST: -14.01 )
CBST' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -41.9   Max: 106.1
Current: -14.01

-41.9
106.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU6.Germany,
Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.
» More Articles for CBST

Headlines

Articles On GuruFocus.com
Mario Gabelli's Top 5 Stock Picks Mar 30 2015 
Prem Watsa Buys 2 and Sells 1 Stock in Fourth Quarter Feb 16 2015 
Mario Gabelli's Top 5 New Stock Buys of Q4 Feb 05 2015 
Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
Everything you need to know about the $8.4B acquisition of Synageva May 06 2015
Superbugs Turn Big Pharma, Gov't Focus To Antibiotics Apr 09 2015
Mario Gabelli's Top 5 Stock Picks Mar 31 2015
Farallon Capital Starts New Position in Cubist Pharmaceuticals Mar 20 2015
Tetraphase looks to double its cash with stock offering Mar 10 2015
Layoffs at Cubist come amid a steady flow of senior execs out of Merck Mar 06 2015
Elliott Management exits position in Covidien Mar 04 2015
Elliott Management starts new position in Cubist Pharmaceuticals Mar 02 2015
Prem Watsa's Stock Buys and Sells of Q4 Feb 17 2015
Dana Holding Set to Join the S&P MidCap 400 Jan 20 2015
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
Teixobactin And iChip Promise Hope Against Antibiotic Resistance Jan 08 2015
Cramer's Mad Dash: Pharma movers Dec 24 2014
Approval of new antibiotic by Cubist to help in $100 trillion global fight Dec 22 2014
FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
Merck Begins Tender Offer to Acquire Cubist Dec 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK